| 26.357 0.307 (1.18%) | 04-14 09:35 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.75 | 1-year : | 37.09 |
| Resists | First : | 27.19 | Second : | 31.75 |
| Pivot price | 24.72  |
|||
| Supports | First : | 20.36 | Second : | 16.13 |
| MAs | MA(5) : | 26.19 |
MA(20) : | 23.54 |
| MA(100) : | 17.82 |
MA(250) : | 17.32 |
|
| MACD | MACD : | 2  |
Signal : | 1.9 |
| %K %D | K(14,3) : | 87.8 |
D(3) : | 91.7 |
| RSI | RSI(14): 69.7 |
|||
| 52-week | High : | 27.19 | Low : | 12.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ETON ] has closed below upper band by 25.2%. Bollinger Bands are 60.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 26.61 - 26.75 | 26.75 - 26.87 |
| Low: | 24.99 - 25.17 | 25.17 - 25.32 |
| Close: | 25.78 - 26.05 | 26.05 - 26.28 |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Wed, 08 Apr 2026
Eton Pharmaceuticals (NASDAQ:ETON) Hits New 1-Year High - Time to Buy? - MarketBeat
Thu, 02 Apr 2026
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tue, 31 Mar 2026
Eton Pharmaceuticals (NASDAQ:ETON) Sets New 52-Week High - Here's Why - MarketBeat
Tue, 31 Mar 2026
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Down 14.4% in March - MarketBeat
Tue, 24 Mar 2026
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Thu, 19 Mar 2026
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 58.7 (%) |
| Shares Short | 1,900 (K) |
| Shares Short P.Month | 2,110 (K) |
| EPS | -0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.97 |
| Profit Margin | -5.8 % |
| Operating Margin | 20.9 % |
| Return on Assets (ttm) | 3.5 % |
| Return on Equity (ttm) | -18.2 % |
| Qtrly Rev. Growth | 82.6 % |
| Gross Profit (p.s.) | 1.75 |
| Sales Per Share | 2.93 |
| EBITDA (p.s.) | 0.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 11 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | -153.24 |
| PEG Ratio | 0 |
| Price to Book value | 26.85 |
| Price to Sales | 8.88 |
| Price to Cash Flow | 67.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|